A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Cancer
Interventions: DRUG: 131I-F16SIP Radioimmunotherapy (RIT)
Sponsor: Philogen S.p.A.
Collaborators: Eudax S.r.l.